13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001622627
Total reported value
$269.2M
$269.2M
40 檔
31.0%
In Q4 2024, Rosalind Advisors, Inc.'s U.S. equity holdings reached a combined market value of $269.2M, distributed across 40 disclosed stock positions.
During Q4 2024, Rosalind Advisors, Inc.'s portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | DCTH | Delcath Systems Inc | Stock-Other | 16.32% | +3.13% | — | |
| 2 | MYO | Myomo Inc | Stock-Other | 9.88% | +0.37% | -0.74% | |
| 3 | ✓ | Mediwound LTD | Stock-Other | 5.72% | -0.76% | — | |
| 4 | CMRXEUR | Chimerix Inc | Stock-Other | 5.43% | — | — | |
| 5 | XERS | Xeris Biopharma Holdings Inc | Stock-Other | 5.38% | +1.03% | — | |
| 6 | ABEO | Abeona Therapeutics Inc | Stock-Other | 5.14% | — | -1.45% | |
| 7 | OCUL | Ocular Therapeutix Inc | Stock-Other | 4.93% | — | +27.54% | |
| 8 | URGN | UroGen Pharma Ltd. | Stock-Other | 4.74% | — | — | |
| 9 | SVRA | Savara Inc | Stock-Other | 4.17% | +0.24% | — | |
| 10 | FENC | Fennec Pharmaceuticals Inc | Stock-Other | 4.07% | +5.54% | — | |
| 11 | HELP | Cybin Inc | Stock-Other | 3.66% | +1.85% | — | |
| 12 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 3.56% | — | -45.45% | |
| 13 | NSPR | Inspiremd Inc | Stock-Other | 3.36% | -1.54% | -0.73% | |
| 14 | OPTNUSD | Optinose Inc | Stock-Other | 3.00% | — | — | |
| 15 | PROF | Profound Medical CORP | Stock-Other | 2.66% | -0.11% | +42.43% | |
| 16 | VSTM | Verastem Inc | Stock-Other | 2.38% | +1.11% | — | |
| 17 | TRVI | Trevi Therapeutics Inc | Stock-Other | 2.24% | — | +41.67% | |
| 18 | ✓ | Cassava Sciences Inc | Stock-Other | 1.87% | — | +13.61% | |
| 19 | REPL | Replimune Group Inc | Stock-Other | 1.61% | — | — | |
| 20 | ✓ | Polypid LTD | Stock-Other | 1.58% | -0.32% | +49.89% | |
| 21 | ✓ | Biomea Fusion Inc | Stock-Other | 1.41% | — | — | |
| 22 | CMPS | Compass Pathways PLC | Stock-Other | 1.37% | — | -9.44% | |
| 23 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 1.32% | — | — | |
| 24 | ACOG | Alpha Cognition Inc | Stock-Other | 0.76% | — | — | |
| 25 | FLNA | Filana Therapeutics Inc | Stock-Other | 0.50% | — | — | |
| 26 | ✓ | Cormedix Inc | Stock-Other | 0.47% | — | -73.73% | |
| 27 | BFRI | Biofrontera Inc | Stock-Other | 0.45% | +0.07% | +63.86% | |
| 28 | KPRX | Kiora Pharmaceuticals Inc | Stock-Other | 0.42% | — | — | |
| 29 | ✓ | Edgewise Therapeutics Inc | Stock-Other | 0.41% | — | — | |
| 30 | ✓ | Ishares Tr | Stock-Other | 0.21% | +0.04% | NEW | |
| 31 | ✓ | Invesco QQQ Tr Put Option 06/2 | Stock-Other | 0.18% | -0.42% | EXIT | |
| 32 | TLPH | Talphera Inc | Stock-Other | 0.16% | +0.97% | -19.11% | |
| 33 | ✓ | Spdr Series Trust | Stock-Other | 0.16% | +0.01% | NEW | |
| 34 | ✓ | Neumora Therapeutics Inc. | Stock-Other | 0.15% | — | — | |
| 35 | ✓ | Lexicon Pharmaceuticals Inc | Stock-Other | 0.14% | — | — | |
| 36 | OWLT | Owlet Inc | Stock-Other | 0.11% | — | -81.69% | |
| 37 | ✓ | Stock-Other | 0.05% | — | — | ||
| 38 | RLMD | Relmada Therapeutics Inc | Stock-Other | 0.03% | — | — | |
| 39 | ✓ | Spdr Series Trust | Stock-Other | 0.01% | — | — | |
| 40 | ✓ | Candel Therapeutics Inc | Stock-Other | — | — | — |
According to official SEC Form 13F filings, Rosalind Advisors, Inc. reported a total U.S. public equity portfolio value of $269.2M across 40 disclosed positions in Q4 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including DCTH, MYO, MEDIWOUND LTD) accounted for 31.0% of total reported equity market value during Q4 2024.
During Q4 2024, Rosalind Advisors, Inc.'s top holdings by market value included DCTH (16.3%)、MYO (9.9%)、MEDIWOUND LTD (5.7%). The largest single position, DCTH, represented 16.3% of total portfolio value.
In Q4 2024, Rosalind Advisors, Inc. made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.